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Rivers of Evidence
Background
If possible, before a treatment is widely used, the intervention 
should be fairly tested and all best evidence summarised. 
Too often, this type of research has been undertaken in a few 
wealthy countries with a tradition of evaluation and synthesis of 
evidence. This does not have to continue. 
The tale of two methodologies 
i. Randomized trials
Randomised controlled trials, the human experiment, if 
possible and ethical, remain the best source of the effects of any 
treatment (1). Not only will all issues known to affect outcome 
be evenly distributed by randomisation (for example issues such 
as age, sex, and duration of illness), but also variables not yet 
fully understood will be equal across groups of allocation (for 
example genetic pre-disposition or differing lifestyle). There 
are many limitations to the randomised trial methodology. For 
example, when it comes to identification of rare but important 
adverse effects, relatively small trials of short duration may 
fail to find such outcomes (a design limitation). Furthermore, 
reporting of adverse effects may be problematic or biased—a 
limitation of conduct—that can reduce the value of any specific 
randomised trial. Nevertheless, despite limitations or threats to 
validity, the well planned conducted and reported randomised 
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Abstract
There has been too much of a one-way flow drift down a river 
of evidence. Researchers from rich countries have produced 
the primary evidence which they proceed to summarise within 
reviews. These summaries have directed care worldwide. However, 
things are changing and the river of evidence can flow in the other 
direction. The care of women with eclampsia has been changed or 
refined throughout the world because of a large low and middle 
income country trial. The global care of people with heart disease 
has been greatly modified by studies originating in China. The care 
of people who are acutely aggressive because of psychosis has to be 
reconsidered in the light of the evidence coming from Brazil and 
India. Healthcare is an issue everywhere and evaluation of care is 
not the premise of any one culture—the evidence—river must run 
both ways.
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controlled trial remains the ‘gold standard’ by which care is 
evaluated.
ii. Reviews
No one can know all relevant controlled trials in their area. 
The need to summarise the totality of evidence has been long-
recognised—even to do that in a way that is systematic and 
scientific (2)—but, reviews of the literature have traditionally 
been qualitative, based on experience, wisdom and consensus. 
Only relevantly recently has this process of reviewing been the 
wide focus of careful scientific scrutiny in itself. Pioneers in this 
‘secondary research’ piloted systematic review techniques (3) 
that have now evolved, and became partly industrialised in the 
form of the Cochrane Collaboration (4).  This Collaboration 
facilitates the production and maintenance of systematically 
conducted reviews of the effects of healthcare. It supplies 
training, general support, and free software for these reviews to 
be conducted, and a means by which they are globally distributed 
(within the Cochrane Library).
Direction of flow
The rivers of evidence, however, have tended to flow in one 
direction. Researchers from rich countries have tended to 
undertake both the trials and the underpinning systematic 
reviews, making interpretation and applicability of results to 
less affluent healthcare systems problematic. Care of people 
with schizophrenia is an interesting and useful example. This 
illness has a lifetime prevalence of 1%, irrespective of social 
class, affluence, region or race (5). We therefore know that 1% 
of people with schizophrenia will live in Iran, another 1% in 
the UK, 5% in the USA, 20% in India and 80% in the group 
of low or middle-income countries. Sheer weight of population 
predicts societal burden of illness. However, the best predictor 
of national trial output for schizophrenia randomised trials is 
Gross Domestic Product (GDP)—not the number of people 
with schizophrenia in that country, nor the estimate of the 
spread of wealth per capita, nor indicators of technological 
advance (6). The USA, with only 5% of the world’s population of 
people with the illness, produces more than 50% of all relevant 
trials. The USA, Europe and Australia are generous producers 
of randomised studies, the results of which are used worldwide. 
Largely these trials, understandably, focus on people within the 
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‘home’ population and care culture. For healthcare professionals, 
as well as patients in the Middle and Far East, in India as well 
as across South America, there is the issue of giving or receiving 
treatment because of findings from trials designed in very 
different settings. These trials, then summarised by consensus, 
were disseminated within reviews that tended to flow out 
from the producer nations—US—generated data tended to be 
reviewed by US reviewers and then disseminated worldwide. 
This situation was further perpetuated by migration of well-
trained doctors from less affluent care cultures to high-income 
countries. Upon return, these doctors would have influenced 
and helped encourage adoption of the affluent-society patterns 
of care that they have become familiar with.
There are really good things within this flow on the river of 
evidence. Although the methods of fairly testing interventions 
have been known for hundreds of years (7), the first widely 
recognised randomised controlled trial came out of post-
World War II England (8). The first systematic review, although 
preceded by an understanding of what was needed by centuries, 
was published by the US (3,9). Methods have substantially 
evolved and now a global accessibility to methods of undertaking 
systematic reviews through the Cochrane Collaboration started 
in England (10).
Changes in direction
The future is likely to bring many more systematically 
conducted reviews, mirroring greater numbers of randomised 
controlled trials. Healthcare professionals in poor countries 
have always generated traditional reviews, qualitative rather 
than quantitative, based more on experience and wisdom. The 
systematic and quantitative reviews of care tended to come 
from more privileged care and research traditions. Although 
the traditional and the systematic review may concur in their 
findings, sometimes they do not, and it is difficult to appreciate 
where discrepancy is occurring—authoritative traditional 
reviews have shown to be recommending lethal interventions 
(11). The rich-down direction of systematic evidence flow need 
not necessarily continue. The logic of systematic reviews is now 
widely acceptable, training is available, tools are universal and 
disseminations are often free. For example, as the war in Syria 
continues, researchers support the insatiable curiosity of groups 
of medical students by running workshops on systematic reviews 
in Damascus (12). As a result, the Cochrane Schizophrenia 
Group has more systematic reviews coming from Damascus 
than it does from the whole of the USA. These reviews, not only 
are applicable to the people of Syria, but are used worldwide and 
have been incorporated into WHO guidance (13).
These reviews, however, tend to summarise trials undertaken 
by privileged societies. Out of necessity, the expensive highly 
explanatory trials have been undertaken in rich countries. 
Regulatory authorities demand high levels of certainty regarding 
the diagnosis of who enters a trial, rather rigid care regimes, and 
scrupulous measurement of outcomes (14). The nature of this 
design, of course, makes it problematic to interpret for every 
day care where people may not be as thoroughly diagnosed, 
care regimes do vary from day to day, and outcomes are not 
measured on rating scales but are to do with life functioning, 
service utility and obvious side effects. Only relatively latterly 
have clinicians and consumers opinion been heeded and more 
pragmatic design introduced. This latter type of study tends 
to be more clinically valuable (14)—but also less expensive to 
undertake.
There are examples right across healthcare. The care of women 
with eclampsia has been changed or refined throughout the 
world because of a large trial coming from low and middle 
income countries (15). The global care of people with heart 
disease has been greatly modified by studies originating in 
China (16). There are good examples from mental health care 
too. The series of TREC (Tranquilização Rápida-Ensaio Clínico), 
translated as rapid tranquillisation-clinical trials, from Brazil 
and India were designed by researchers in these countries who 
had discovered that treatments for people were  acutely violent 
because psychotic illnesses were grossly under-researched. The 
teams undertook the world’s largest studies in this area, and 
recorded outcomes that were of interest to these care cultures 
(17–21). These trials have been widely recognised as being 
“unlike most of the other studies in this [area of research, the 
TREC studies], were large studies of a high methodological 
quality” (22). These randomised trial studies did not copy 
what had been done before—they bettered those methods. All 
ran on infrastructure funding alone. They were undertaken 
by interested researchers and clinicians, because they wished 
to know the answer. These researchers wanted to disseminate 
good evidence to the rest of the world, and show the research 
community that good evidence can come from less privileged 
situations. They wanted to show the perverse advantage of those 
less privileged situations for generation of good, very widely 
applicable, evidence. As researchers in less privileged situations 
gain confidence, are supported, look out into the world of 
research and have access to disseminate in globally accessible 
forms, more two directional flow of the river can be expected.
Conclusion
With courage and leadership, good science is possible almost 
anywhere. If allowed to question, and doors are not held closed, 
interested researchers can objectively evaluate treatments 
employing ‘gold standard’ methodology—with enormous 
repercussions on local and international care. Although there 
are examples of pioneering work from the Middle East, these 
examples remain too few. There are the same numbers of people 
with, for example, schizophrenia, in the Middle East as there 
are in the USA, yet only a handful of trials come from Arab or 
Persian lands (23) and this is not all to do with GDP. This dearth 
of local good evidence applies to other areas of medicine too. 
For far too long, the river has flowed only one way. Generous 
political and research leadership would allow a natural 
flourishing of local research—for, at the very least, local needs. 
The global accessibility of systematic review techniques and 
recognition of the importance of pragmatic randomised trials 
are opportunities for anyone wanting to generate high grade 
evidence of better quality than has been seen before.
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